Tyra Biosciences, Inc. Annual Report: A 2025 Performance Review for Investors

Considering an investment in Tyra Biosciences? This guide provides a clear, jargon-free overview of the company's 2025 performance, helping you understand its progress and decide if it aligns with your investment goals.

This report covers Tyra's performance for the fiscal year that ended on December 31, 2025. You can find their stock trading on the Nasdaq Global Select Market under the ticker symbol TYRA.

---

1. Business Overview

Tyra Biosciences is a precision oncology company that develops new medicines for cancer patients. Its focus is on those who have become resistant to current targeted treatments. Tyra designs highly selective small molecule inhibitors to overcome specific genetic changes that drive cancer growth and drug resistance. The company uses its proprietary discovery platform to identify and develop leading therapies for difficult-to-treat cancer targets.

As an "Emerging Growth Company," "Smaller Reporting Company," and "Non-accelerated Filer," Tyra benefits from fewer reporting requirements. This allows the company to direct more resources toward research and development (R&D). This status also indicates Tyra's earlier stage of development, suggesting higher growth potential but also greater risk compared to larger, more established pharmaceutical companies.

---

2. Financial Performance

For the fiscal year ended December 31, 2025:

• Revenue: Tyra reported approximately $5.2 million in minimal revenue, mainly from research grants and a small collaboration agreement. This is typical for a biotech company in its development phase, as it focuses on R&D rather than commercial sales.
• Net Loss: The company recorded a net loss of $125.8 million, due to significant investment in its research and development pipeline.
• R&D Expenses: Research and development expenses totaled $105.5 million, a significant increase from the prior year. This rise was mainly driven by advancing its lead clinical candidates and expanding its discovery pipeline.
• General & Administrative Expenses: General and administrative expenses reached $25.1 million, covering corporate functions, legal, and administrative support.
• Market Valuation: As of June 30, 2025, common stock held by non-affiliates had a market value of $297.3 million. On February 25, 2026, the company had 53.9 million shares of common stock outstanding.
• Year-over-Year Changes: The significant increase in R&D expenses indicates a substantial rise in operational costs compared to the prior year. This aligns with a company progressing its clinical pipeline. At this stage, Tyra primarily measures growth by pipeline progression and achieving clinical milestones, rather than traditional revenue growth.

---

3. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

Overview: This section reviews Tyra Biosciences, Inc.'s financial condition and operational results for the fiscal year ended December 31, 2025. As a clinical-stage biotechnology company, Tyra's financial performance primarily involves significant investments in research and development (R&D) and resulting net losses, as it focuses on advancing drug candidates through clinical trials.

Results of Operations:

• Revenue: Tyra generated minimal revenue of $5.2 million in 2025, mainly from research grants and a small collaboration agreement. This is typical for the company's development stage, as it has no commercial products and therefore generates no revenue from product sales.
• Research and Development (R&D) Expenses: R&D expenses were the main driver of expenditures, totaling $105.5 million. This substantial investment shows the company's strategic focus on advancing its pipeline. Key drivers for this increase included:
  • Successfully initiating a Phase 2 clinical trial for its lead candidate, TYRA-200, which targets FGFR3-mutated bladder cancer.
  • Advancing two additional pre-clinical candidates into IND-enabling studies (the final studies before human trials).
  • Increased personnel costs from expanding its scientific and clinical teams, including appointing a new Chief Medical Officer.
  • Investing in its proprietary discovery platform. This increased R&D spending contributed to a higher cash burn rate during the year.
• General and Administrative (G&A) Expenses: G&A expenses reached $25.1 million, mainly covering personnel costs for administrative functions, professional fees (legal, accounting, consulting), and other corporate overhead to support operations and public company compliance.
• Net Loss: The net loss of $125.8 million for 2025 directly results from the significant R&D investments and G&A expenses, as expected for a clinical-stage company without commercial products.

Liquidity and Capital Resources:

• Cash Position: As of December 31, 2025, Tyra held cash, cash equivalents, and marketable securities totaling $185.0 million.
• Debt: The company reported no significant long-term debt, maintaining a strong, low-debt balance sheet.
• Liquidity and Cash Runway: Based on current projections and expected R&D spending, Tyra estimates its existing cash resources are enough to fund operations until Q3 2027. This assumes continued pipeline investment and operational expenses at current or slightly higher rates.
• Future Capital Needs: The company expects to need significant additional capital to fund operations beyond Q3 2027. This capital is especially crucial to complete ongoing clinical trials, advance its pipeline to commercialization, and potentially expand discovery efforts. Potential sources include equity offerings, strategic partnerships, or debt financing. Market conditions and the company's clinical progress determine the availability and terms of such financing. This need for additional capital is a key challenge requiring careful monitoring.

Off-Balance Sheet Arrangements: As of December 31, 2025, Tyra Biosciences, Inc. had no off-balance sheet arrangements likely to affect its financial condition, revenues, expenses, operations, liquidity, capital expenditures, or resources.

Contractual Obligations: The company's main contractual obligations involve operating leases for its facilities and commitments from various research and development agreements. These obligations align with operational needs, and the company expects to fund them through existing cash and future capital raises.

---

4. Financial Health

• Cash Position: As of December 31, 2025, Tyra held $185.0 million in cash, cash equivalents, and marketable securities.
• Debt: The company reported no significant long-term debt, showing a healthy, low-debt balance sheet.
• Liquidity: Based on current projections and R&D spending, Tyra estimates its existing cash resources are enough to fund operations until Q3 2027. However, as discussed in the MD&A, the company will need future capital raises—potentially through equity offerings or strategic partnerships—to complete clinical trials and advance its pipeline to commercialization. This highlights the need to carefully monitor their cash runway and future financing plans.

---

5. Risk Factors

The company highlights that "known and unknown risks, uncertainties, and other important factors" could cause actual results to differ from expectations. Specific risks include:

• Clinical Trial Success: The primary risk involves successfully developing and gaining regulatory approval for its drug candidates. Clinical trials are uncertain, lengthy, and expensive. Failures at any stage (e.g., in efficacy, safety, or due to patient enrollment delays) could significantly impact the company's value and future.
• Regulatory Approval: Gaining FDA and international regulatory approvals is a complex, lengthy, and uncertain process. No guarantee exists that any of Tyra's drug candidates will receive necessary approvals.
• Competition: The precision oncology market is highly competitive, with larger pharmaceutical companies and other biotechs developing similar or alternative therapies. Tyra's ability to compete effectively depends on its drug candidates' differentiation, efficacy, and safety profiles.
• Need for Additional Financing: Tyra will need substantial additional funding to continue operations and advance its pipeline. This capital may not be available on favorable terms or at all, potentially delaying development, scaling back operations, or significantly diluting existing shareholders through equity offerings.
• Intellectual Property: Protecting its proprietary technology and drug candidates through patents and other intellectual property rights is critical. Challenges to its intellectual property, or failure to obtain or maintain adequate protection, could adversely affect its business.
• Reliance on Key Personnel: The company's success heavily depends on attracting and retaining highly qualified scientific, clinical, and management personnel. Losing key individuals could disrupt operations and development efforts.
• Manufacturing and Supply Chain: Relying on third-party manufacturers for its drug candidates introduces risks related to quality, capacity, and timely supply.

---

6. Competitive Positioning

Tyra differentiates itself with its proprietary small molecule kinase inhibitor platform, a technology designed to overcome acquired resistance mutations in cancer. This platform enables the rational design of highly selective inhibitors. Its lead program, TYRA-200, targets specific FGFR3 mutations, addressing a niche with significant unmet medical need where existing therapies may be limited or cause resistance. While facing competition from established oncology players and other biotech firms with FGFR inhibitors, Tyra aims to offer leading solutions with improved selectivity, efficacy, and a focus on overcoming resistance mechanisms. The company believes its targeted approach gives it a competitive advantage in specific patient populations.

---

7. Future Outlook

For 2026, Tyra plans to:

• Report initial data from the Phase 2 trial of TYRA-200 in late 2026, a critical milestone for the company.
• Initiate a Phase 1 trial for its second lead candidate, TYRA-300, in early 2027, further expanding its clinical pipeline.
• Continue expanding its discovery platform to identify new targets for precision oncology, reinforcing its long-term pipeline strategy.
• Actively pursue strategic partnerships to potentially accelerate development and commercialization of its candidates, and to secure non-dilutive funding.
• The company expects continued significant R&D spending as it advances clinical programs and expands research efforts.

Strategic Focus: Tyra's overall strategic focus remains on advancing its precision oncology pipeline. It will increasingly explore potential combination therapies for its lead candidates to broaden their market potential and address complex resistance mechanisms. The company also reviewed its early-stage pipeline to prioritize programs with the highest probability of success and market impact, optimizing resource allocation.

---

8. Market Trends and Regulatory Environment

Tyra benefits from a favorable market trend toward precision medicine and targeted therapies in oncology. This area continues to attract significant investment and regulatory support, such as accelerated approval pathways for therapies addressing unmet needs. While stringent, the regulatory environment for oncology drugs has shown flexibility for innovative therapies, especially those addressing rare mutations or resistance mechanisms. However, increasing scrutiny on drug pricing and reimbursement policies could impact future commercial success and market access for new therapies. The company continuously monitors these trends to adapt its development and commercialization strategies.